Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin

por Coleman, Emily, Panse, Gauri, Haldas, Jason, Gettinger, Scott N., Leventhal, Jonathan S.
Publicado 2018

Immuno-thermal ablations – boosting the anticancer immune response

por Slovak, Ryan, Ludwig, Johannes M., Gettinger, Scott N., Herbst, Roy S., Kim, Hyun S.
Publicado 2017

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

por Dhodapkar, Kavita M, Gettinger, Scott N, Das, Rituparna, Zebroski, Henry, Dhodapkar, Madhav V
Publicado 2013

Oncolytic virus immunotherapy: future prospects for oncology

por Raja, Junaid, Ludwig, Johannes M., Gettinger, Scott N., Schalper, Kurt A., Kim, Hyun S.
Publicado 2018

Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy

por Adam, Lucas C., Raja, Junaid, Ludwig, Johannes M., Adeniran, Adebowale, Gettinger, Scott N., Kim, Hyun S.
Publicado 2018

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

por Carvajal-Hausdorf, Daniel, Altan, Mehmet, Velcheti, Vamsidhar, Gettinger, Scott N., Herbst, Roy S., Rimm, David L., Schalper, Kurt A.
Publicado 2019

Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

por Uhlig, Johannes, Case, Meaghan Dendy, Blasberg, Justin D., Boffa, Daniel J., Chiang, Anne, Gettinger, Scott N., Kim, Hyun S.
Publicado 2019

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

por Suozzi, Kathleen C., Stahl, Maximilian, Ko, Christine J., Chiang, Anne, Gettinger, Scott N., Siegel, Mark D., Bunick, Christopher G.
Publicado 2016

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

por Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius
Publicado 2022

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

por Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Publicado 2021

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

por Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Drilon, Alexander, Wolchok, Jedd D., Carvajal, Richard D., McHenry, M. Brent, Hosein, Fareeda, Harbison, Christopher T., Grosso, Joseph F., Sznol, Mario
Publicado 2019

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

por Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C. H., Han, Ji-Youn, Hochmair, Maximilian J., Lee, Ki Hyeong, Delmonte, Angelo, García Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander, Gettinger, Scott N., Tiseo, Marcello, Lin, Huamao M., Gupta, Neeraj, Hanley, Michael J., Ni, Quanhong, Zhang, Pingkuan, Popat, Sanjay
Publicado 2020

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

por Gettinger, Scott N., Huber, Rudolf M., Kim, Dong-Wan, Bazhenova, Lyudmila, Hansen, Karin Holmskov, Tiseo, Marcello, Langer, Corey J., Paz-Ares Rodríguez, Luis G., West, Howard L., Reckamp, Karen L., Weiss, Glen J., Smit, Egbert F., Hochmair, Maximilian J., Kim, Sang-We, Ahn, Myung-Ju, Kim, Edward S., Groen, Harry J.M., Pye, Joanna, Liu, Yuyin, Zhang, Pingkuan, Vranceanu, Florin, Camidge, D. Ross
Publicado 2022

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

por Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.
Publicado 2018